Treatment of HCV infection with direct-acting antiviral agents. Real life experiences from the Euro-Asian region

Approximately 808 patients were treated with sofosbuvir-based DAAs with or without Ribavirin for 12 or 24 weeks, whereas 416 patients were treated with the Paritaprevir, Ombitasvir, Ritonavir.Dasabuvir (PROD) regimen with or without Ribavirin for 12 weeks or 24 weeks.Results: At the end of follow-up examinations, 1183 patients (97.93%) had sustained virological response (SVR), 17 (1.40%) died of reasons unrelated to the treatment regimen, 12 had recurrence after treatment, and 129 (10.67%) had adverse events like anemia, itching, and weakness.Conclusion: In this large cohort of HCV-infected patients, treatment with DAAs yielded a high overall SVR rate of 97.93%.

📌 3 Key Takeaways

🎯

Objective & Hypothesis:Background/Aims: Hepatitis C virus (HCV) infection is a common disease that causes liver cirrhosis, hepatocellular carcinoma, and extra hepatic manifestations with high mortality and morbidity rates.

📊

Key Findings & Data:This study aimed to present real-life experiences and results of treatment of HCV infection with direct-acting antiviral agents (DAAs) from the Euro-Asian region, including Turkey and Azerbaijan.Materials and Methods: A total of 1224 patients with chronic HCV infection were treated with DAAs in accordance with the international guidelines for the management of HCV infection.

💡

Conclusion & Impact:Approximately 808 patients were treated with sofosbuvir-based DAAs with or without Ribavirin for 12 or 24 weeks, whereas 416 patients were treated with the Paritaprevir, Ombitasvir, Ritonavir.Dasabuvir (PROD) regimen with or without Ribavirin for 12 weeks or 24 weeks.Results: At the end of follow-up examinations, 1183 patients (97.93%) had sustained virological response (SVR), 17 (1.40%) died of reasons unrelated to the treatment regimen, 12 had recurrence after treatment, and 129 (10.67%) had adverse events like anemia, itching, and weakness.Conclusion: In this large cohort of HCV-infected patients, treatment with DAAs yielded a high overall SVR rate of 97.93%.

🔬Design:Research Article

📍Scope:Comprehensive Sample

⚙️Variables:Domain Parameters

Özet

Background/Aims: Hepatitis C virus (HCV) infection is a common disease that causes liver cirrhosis, hepatocellular carcinoma, and extra hepatic manifestations with high mortality and morbidity rates. This study aimed to present real-life experiences and results of treatment of HCV infection with direct-acting antiviral agents (DAAs) from the Euro-Asian region, including Turkey and Azerbaijan.Materials and Methods: A total of 1224 patients with chronic HCV infection were treated with DAAs in accordance with the international guidelines for the management of HCV infection. The mean age was 58.74±14.75 years, with 713 (58.25%) females. The genotypes of the patients were as follows: genotype 1b, 83.36% (n=1024); genotype 1a, 8.08% (n=99); genotype 2, 2.85% (n=35); genotype 3, 3.34% (n=41); genotype 4, 1.71% (n=21); and combined genotypes, 0.32% (n=4). Approximately 808 patients were treated with sofosbuvir-based DAAs with or without Ribavirin for 12 or 24 weeks, whereas 416 patients were treated with the Paritaprevir, Ombitasvir, Ritonavir.Dasabuvir (PROD) regimen with or without Ribavirin for 12 weeks or 24 weeks.Results: At the end of follow-up examinations, 1183 patients (97.93%) had sustained virological response (SVR), 17 (1.40%) died of reasons unrelated to the treatment regimen, 12 had recurrence after treatment, and 129 (10.67%) had adverse events like anemia, itching, and weakness.Conclusion: In this large cohort of HCV-infected patients, treatment with DAAs yielded a high overall SVR rate of 97.93%. DAAs were safe and well-tolerated. Thus, the elimination of HCV infection is no longer a dream worldwide.

🔖

Cite This Article

ÖRMECİ, N., GÜLŞEN, M. T., SEZGİN, O., AGHAYEVA, S., DEMİR, M., KÖKSAL, İ., GÜNER, R., ERASLAN, E., ASİLLER, Ö. Ö., BALKAN, A., YARAŞ, S., KARTAL, A. Ç. (2020). Treatment of HCV infection with direct-acting antiviral agents. Real life experiences from the Euro-Asian region. Turkish Journal of Gastroenterology, Cilt: 31 - Sayı: 2, 148–155. https://ajindex.com/articles/408670

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (14)

Younossi ZM, Tanaka A, Eguchi Y, et al. The impact of hepatitis C virus outside the liver: evidence from asia. Liver Int 2017; 37: 159-72
GBD 2013 Mortality and Causes of Death Collaborators. Global, region al, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014; 385: 117-71
European association for the study of the liver EASL clinical prac tice guidelines: management of hepatitis C virus infection. J Hepatol 2014; 60: 392-420
Omata M, Kanda T, Wei L, et al. APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and lab oratory testing. Hepatol Int 2016; 10: 681-701
AASLD-IDSA HCV Guidance Panel. Hepatitis C Guidance 2018 Update: AASLD-IDSA Rec-ommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Clin Infect Dis 2018; 67: 1477-92
Kowdley KV, Kowdley KV, Sundaram V, et al. Eight weeks of Ledi pasvir/Sofosbuvir is ef-fective for selected patients with genotype 1 hepatitis C virus infection. Hepatology 2017; 65: 1094-103
Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and Sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370: 1483-93
Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and Sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370: 1889- 98
Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and Sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014; 370: 1879-888
Backus LI, Belperio PS, Shahoumian TA, Loomis TP, Mole LA. Real-World Effectiveness of Ledipasvir/ Sofosbuvir in 4,365 Treat ment-Naive, Genotype 1 Hepatitis C-Infected Patients. Hepatology 2016; 64: 405-14
Butt AA, Yan P, Shaikh OS, et al. Sofosbuvir-based regimens in clinical practice achieve SVR rates closer to clinical trials: results from ERCHIVES. Liver Int 2016; 36: 651-65
Welzel TM, Petersen J, Herzer K, et al. Daclatasvir plus Sofosbu vir, with or without Rib-avirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort. Gut 2016; 65: 1861-70
Poordad F, Hezode C, Trinh R, et al. ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis. N Engl J Med 2014; 370: 1973-82
Ahmed H, Abushouk AI, Menshawy A, et al. Perspective managing adverse effects and complications in c